14 Lung Cancer Clinical Trials in Santa Monica, CA (2026)

Q: How do I join a clinical trial in Santa Monica?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Santa Monica research site will contact you.

Recruiting Lung Cancer Studies in Santa Monica

NCT05899608Recruiting

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non...

Santa Monica, CAPHASE31,600 participantsSummit Therapeutics

View Study Details

NCT04389632Recruiting

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will ...

Santa Monica, CAPHASE11,006 participantsSeagen, a wholly owned subsidiary of Pfizer

View Study Details

NCT06561386Recruiting

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squa...

Santa Monica, CAPHASE31,000 participantsBristol-Myers Squibb

View Study Details

NCT05379985Recruiting

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors....

Santa Monica, CAPHASE1754 participantsRevolution Medicines, Inc.

View Study Details

NCT06892548Recruiting

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

This study aims to investigate the combination of BNT324, a B7-H3 antibody-drug conjugate (ADC) with BNT327, a programmed death-ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF) bispecifi...

Santa Monica, CAPHASE1594 participantsBioNTech SE

View Study Details

NCT06350097Recruiting

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

The purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Dato-DXd (i.v. infusion) compared with osimertinib (tablet) monotherapyas a first-line therapy ...

Santa Monica, CAPHASE3582 participantsAstraZeneca

View Study Details

NCT05983432Recruiting

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors....

Santa Monica, CAPHASE1470 participantsSystImmune Inc.

View Study Details

NCT06452277Recruiting

A Study to Learn More About How Well Sevabertinib (BAY 2927088) Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutat...

Santa Monica, CAPHASE3444 participantsBayer

View Study Details

NCT07195695Recruiting

Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

This study is open to adults 18 years and older who have early-stage non-small cell lung cancer (NSCLC). Their cancer must have a specific change in a gene called HER2. Genes provide the instructions ...

Santa Monica, CAPHASE3400 participantsBoehringer Ingelheim

View Study Details

NCT06343402Recruiting

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

A first in human study to evaluate the safety and preliminary antitumor activity of BBO-8520, a KRAS G12C (ON and OFF) inhibitor, as a single agent and in combination with pembrolizumab and BBO-10203 ...

Santa Monica, CAPHASE1350 participantsTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

View Study Details

NCT07005128Recruiting

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolon...

Santa Monica, CAPHASE3330 participantsAmgen

View Study Details

NCT07098338Recruiting

A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

This is a Phase II, multi-center, open-label platform study evaluating novel combination treatment options in participants with locally advanced or metastatic NSCLC. The study will consist of several ...

Santa Monica, CAPHASE2278 participantsAstraZeneca

View Study Details

NCT06772623Recruiting

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worldwide. The purpose of this study is to as...

Santa Monica, CAPHASE1252 participantsAbbVie

View Study Details

NCT05877599Recruiting

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A\*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant solid tumors....

Santa Monica, CAPHASE145 participantsAstraZeneca

View Study Details

About Lung Cancer Clinical Trials in Santa Monica

Lung cancer is the leading cause of cancer death worldwide, starting in the cells of the lungs. The two main types are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Treatments include surgery, chemotherapy, radiation, immunotherapy, and targeted drugs.

There are currently 14 lung cancer clinical trials recruiting participants in Santa Monica, CA. These studies are seeking a combined 8,105 participants. Research is being sponsored by Summit Therapeutics, Seagen, a wholly owned subsidiary of Pfizer, Bristol-Myers Squibb and 9 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Lung Cancer Clinical Trials in Santa Monica — FAQ

Are there lung cancer clinical trials in Santa Monica?

Yes, there are 14 lung cancer clinical trials currently recruiting in Santa Monica, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Santa Monica?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Santa Monica research site will contact you about next steps.

Are clinical trials in Santa Monica free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Santa Monica studies also compensate for your time and travel.

What lung cancer treatments are being tested?

The 14 active trials in Santa Monica are testing new therapies including novel drugs, biologics, and treatment approaches for lung cancer.

Data updated July 18, 2026 from ClinicalTrials.gov